Mechanisms of killing by anti-CD20 monoclonal antibodies.
about
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivoManagement of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future PerspectivesClinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemiaObinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveNew antibody approaches to lymphoma therapyMonitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodiesResponse to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms: rational design of dosing strategiesAcceptable changes in quality attributes of glycosylated biopharmaceuticalsSilencing of human phosphatidylethanolamine-binding protein 4 enhances rituximab-induced death and chemosensitization in B-cell lymphomaSubcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeysAntibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell linesAntibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy.Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement.Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.A rheumatoid factor paradox: inhibition of rituximab effector function.Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsAntigenic modulation and rituximab resistance.Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cellsDevelopment of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.The mechanism of anti-CD20-mediated B cell depletion revealed by intravital imagingIntravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodiesRituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity.The potential effect of statins on rituximab immunotherapy.Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects.Immunologic effects of rituximab on the human spleen in immune thrombocytopenia.A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome.Cellular immune dysfunction in immune thrombocytopenia (ITP).Combating non-Hodgkin lymphoma by targeting both CD20 and HLA-DR through CD20-243 CrossMabSafety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey.Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case ReportThe role of B cells in lupus pathogenesis.Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functionsImmunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primatesIncreasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
P2860
Q21245712-F61D61F2-CD40-4ACE-AC17-B695069F1B89Q26774815-759E4616-4362-4D93-A2B5-DD7E07CA26DEQ26783600-EA273F28-7DF7-4798-AD59-65746867FFFCQ26796455-3CD094DF-20AC-4038-A664-09970CF0261EQ27022373-3DB9DC47-C4CB-40DC-BE5B-44AD82262AE5Q27345217-42386C3C-C693-495B-9FAA-3B48BCDE43C8Q27692640-8A294EB9-EDC3-4863-8ED4-D067FD64AE7CQ27694769-7518ACC1-5EE3-4D13-954F-B6AC0ADC9FBCQ28235143-9B0AF762-45FC-43D1-B974-A07185812A34Q28486745-DD19C980-E640-4D34-9D8C-547C979858BBQ28535043-E5CC427C-0593-4EB9-96B1-130013E2F523Q28742585-B0211A65-DEB2-42FE-B5F3-C2DCD37F4DF8Q30275229-0E3EF30F-9C8F-4B9A-9B65-A1410AAB325BQ30276243-27C4F743-61C5-483D-9600-355834FD371DQ30356145-FBAC7A58-2E53-4706-840D-CFEE0957402EQ30405847-F49F3844-B5CB-4812-8682-068B8375DCF5Q30418884-CF99FB45-EA6B-455F-B23F-E0B646CC1D5DQ30421637-4B2BC1BF-28FC-439D-86DF-72F7DE2475F0Q30432874-73D17B85-E5EA-43C1-B893-9F404D29F6A6Q30439017-A6800B85-A165-4F7D-8926-B8EFB46248CFQ30489241-5368C617-73CD-4AF3-A434-A2B26AB6DF6DQ30525314-93D939CE-E695-428C-BBE0-444CB821D760Q30559277-AC4C2EE6-9DC7-4E5E-8B77-C89AA75DD666Q30818421-394FE370-A887-4310-8F95-C0C539E0D3CBQ31032919-0DE65D37-961F-435E-B6E7-CED932B8F831Q33325581-5F0544DF-77BC-4548-8246-64036EE8215AQ33388543-286A6DD5-7EF8-46BF-8B3C-08D34A8D647EQ33396902-25171B5F-DEE2-4A38-B87F-994294ACBDBAQ33404206-B9973994-C8E0-4BA7-88F2-E250985F475BQ33409710-0177C153-EA78-49B5-9BBE-919DEF73D53DQ33573605-D5DA434D-0984-4F69-AE0C-687B64F7F185Q33574197-65D9A182-CFCD-470B-8F86-90033447A2F5Q33645793-B5CA4EA2-331F-42F3-9B62-B52AB76E4340Q33673144-623FE56B-CB4D-4F75-91C5-38E8FD09A599Q33698000-1439A697-E92A-4316-95A4-F9A6888119D9Q33716669-87235DD1-857E-439D-B143-FBF82506A33AQ33733443-D264CC3A-B4B7-4BBA-89BB-C1AF7343992FQ33755345-4BBD8627-9635-49C4-82EB-11909FDCE864Q33822191-CA606E24-5A29-4F8D-8153-1394791214EDQ33896738-98193CA0-05B5-46BE-8DDD-EF3D6873F301
P2860
Mechanisms of killing by anti-CD20 monoclonal antibodies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of killing by anti-CD20 monoclonal antibodies.
@en
type
label
Mechanisms of killing by anti-CD20 monoclonal antibodies.
@en
prefLabel
Mechanisms of killing by anti-CD20 monoclonal antibodies.
@en
P2093
P1433
P1476
Mechanisms of killing by anti-CD20 monoclonal antibodies
@en
P2093
Martin J Glennie
Ronald P Taylor
Ruth R French
P304
P356
10.1016/J.MOLIMM.2007.06.151
P50
P577
2007-09-01T00:00:00Z